Literature DB >> 29520673

Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

H Marco1, J Draibe2, J Villacorta3, L F Quintana4, N Martin5, R Garcia-Osuna6, C Cabre7, M A Martín-Gómez8, A Balius9, A Saurina10, M Picazo11, I Gich-Saladich12, M Navarro-Díaz1, M Praga13, T Cavero13, J Ballarin14, M M Díaz-Encarnación15.   

Abstract

The classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) remains controversial. The main objective of this study was to define the respective values of ANCA serotype-based classification, clinicopathological classification, and histopathological classification in predicting patient and renal outcomes in a Spanish cohort of patients with ANCA with specificity for myeloperoxidase, MPO-ANCA, versus ANCA with specificity for proteinase 3, PR3-ANCA. Two hundred and forty-five patients with ANCA-AAV and biopsy-proven renal involvement diagnosed between 2000 and 2104 were recruited in 12 nephrology services. Clinical and histologic data, renal outcomes, and mortality were analyzed. We applied the Chapel Hill Consensus Conference definition with categories for granulomatosis with the polyangiitis (GPA) and microscopic polyangiitis (MPA), the classification based on ANCA specificity, and the histopathological classification proposed in 2010. Eighty-two percent were MPO-ANCA positive and 18.0% PR3-ANCA positive. Altogether, 82.9% had MPA and 17.1% GPA. The median follow-up was 43.2 months (0.1-169.3). Neither ANCA-based serological nor clinical classification was predictive of renal outcomes or patient survival on bivariate or multivariate Cox regression analysis. Histopathological classification was found to predict development of end-stage renal disease (p = 0.005) in Kaplan-Meier analysis. ANCA specificity was more predictive of relapse than clinicopathological classification in multivariate analysis (HR 2.086; 95% CI 1.046-4.158; p = 0.037). In our Spanish cohort, a majority of patients had an MPO-ANCA-AAV. A classification based on ANCA specificity has a higher predictive value for relapse occurrence and could be used for decision-making with respect to induction treatment and maintenance therapies.

Entities:  

Keywords:  Clinicopathological classification; Kidney biopsy; MPO-ANCA; PR3-ANCA; Relapse; Vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29520673     DOI: 10.1007/s10067-017-3973-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  45 in total

1.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne
Journal:  Arthritis Rheum       Date:  2012-02

2.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

Review 3.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

4.  The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study.

Authors:  Francisco Diaz-Crespo; Javier Villacorta; Mercedes Acevedo; Teresa Cavero; Carmen Guerrero; Eugenio García Díaz; Juan Luis Orradre; Miguel Angel Martinez; Manuel Praga; Gema Fernandez-Juarez
Journal:  Hum Pathol       Date:  2016-02-10       Impact factor: 3.466

5.  Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.

Authors:  Bertha M Córdova-Sánchez; Juan M Mejía-Vilet; Luis E Morales-Buenrostro; Georgina Loyola-Rodríguez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

Review 6.  Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature.

Authors:  G Moroni; V Binda; A Leoni; F Raffiotta; S Quaglini; G Banfi; P Messa
Journal:  Clin Exp Rheumatol       Date:  2015-05-26       Impact factor: 4.473

7.  Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis.

Authors:  Alfred Mahr; Sandrine Katsahian; Hugo Varet; Loïc Guillevin; E Christiaan Hagen; Peter Höglund; Peter A Merkel; Christian Pagnoux; Niels Rasmussen; Kerstin Westman; David R W Jayne
Journal:  Ann Rheum Dis       Date:  2012-09-08       Impact factor: 19.103

8.  Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement.

Authors:  Marjan C Slot; Jan Willem Cohen Tervaert; Casper F M Franssen; Coen A Stegeman
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

9.  Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Authors:  Takashi Iwakiri; Shouichi Fujimoto; Kiyoki Kitagawa; Kengo Furuichi; Junya Yamahana; Yunosuke Matsuura; Atsushi Yamashita; Shigehiro Uezono; Yoshiya Shimao; Shuichi Hisanaga; Takeshi Tokura; Takashi Wada; Kazuo Kitamura; Yujiro Asada
Journal:  BMC Nephrol       Date:  2013-06-17       Impact factor: 2.388

10.  Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts.

Authors:  Eri Muso; Tomomi Endo; Mitsuyo Itabashi; Hiroko Kakita; Yukako Iwasaki; Yu Tateishi; Toshiyuki Komiya; Toshiko Ihara; Wako Yumura; Takao Sugiyama; Kensuke Joh; Kazuo Suzuki
Journal:  Clin Exp Nephrol       Date:  2012-12-21       Impact factor: 2.801

View more
  4 in total

1.  Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.

Authors:  Marta Casal Moura; Maria V Irazabal; Alfonso Eirin; Ladan Zand; Sanjeev Sethi; Bijan J Borah; Jeffrey L Winters; James P Moriarty; Rodrigo Cartin-Ceba; Alvise Berti; Misbah Baqir; Gwen E Thompson; Ashima Makol; Kenneth J Warrington; Viengneesee Thao; Ulrich Specks; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2020-08-21       Impact factor: 10.121

2.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

3.  Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis.

Authors:  Shohei Tachibana; Masayuki Iyoda; Taihei Suzuki; Nobuhiro Kanazawa; Ken Iseri; Yukihiro Wada; Kei Matsumoto; Takanori Shibata
Journal:  PLoS One       Date:  2019-11-14       Impact factor: 3.240

4.  Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns.

Authors:  J Oristrell; J Loureiro-Amigo; R Solans; M P Valenzuela; V Monsálvez; A Segarra; M J Amengual; A Marín; C Feijoo; C Tolosa
Journal:  Clin Exp Immunol       Date:  2020-11-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.